Cuker, A., Tseng, E. K., Nieuwlaat, R., Angchaisuksiri, P., Blair, C., Dane, K., DeSancho, M. T., Diuguid, D., Griffin, D. O., Kahn, S. R., Klok, F. A., Lee, A. I., Neumann, I., Pai, A., Righini, M., Sanfilippo, K. M., Siegal, D. M., Skara, M., Terrell, D. R., … Schünemann, H. J. (2022). American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Advances, 6(17), 4915–4923. https://doi.org/10.1182/bloodadvances.2022007561

Moskop, A., Pommert, L., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J.-A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M. L., Satwani, P., Krupski, C., Keating, A. K., … Schultz, L. M. (2022). Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Advances, 6(14), 4251–4255. https://doi.org/10.1182/bloodadvances.2021006393

Loh, K. P., Sanapala, C., Watson, E. E., Jensen-Battaglia, M., Janelsins, M. C., Klepin, H. D., Schnall, R., Culakova, E., Vertino, P., Susiarjo, M., Lin, P.-J., Mendler, J. H., Liesveld, J. L., Huselton, E. J., Taberner, K., Mohile, S. G., & Mustian, K. (2022). A single-arm pilot study of a mobile health exercise intervention (GO-EXCAP) in older patients with myeloid neoplasms. Blood Advances, 6(13), 3850–3860. https://doi.org/10.1182/bloodadvances.2022007056

Addo, O. Y., Mei, Z., Hod, E. A., Jefferds, M. E., Sharma, A. J., Flores-Ayala, R. C., Spitalnik, S. L., & Brittenham, G. M. (2022). Physiologically based serum ferritin thresholds for iron deficiency in women of reproductive age who are blood donors. Blood Advances, 6(12), 3661–3665. https://doi.org/10.1182/bloodadvances.2022007066

Etra, A., Gergoudis, S., Morales, G., Spyrou, N., Shah, J., Kowalyk, S., Ayuk, F., Baez, J., Chanswangphuwana, C., Chen, Y.-B., Choe, H., DeFilipp, Z., Gandhi, I., Hexner, E., Hogan, W. J., Holler, E., Kapoor, U., Kitko, C. L., Kraus, S., … Levine, J. E. (2022). Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood Advances, 6(12), 3707–3715. https://doi.org/10.1182/bloodadvances.2022007296

Pal, I., Grilo, A. M. S., Gaspary, A., Das Sharma, S., Scotto, L., O’Connor, O. A., Jovanovic, M., Deng, C., & Berchowitz, L. E. (2022). Inhibition of casein kinase 1δ disrupts translation initiation and exerts potent antilymphoma activity. Blood Advances, 6(14), 4157–4161. https://doi.org/10.1182/bloodadvances.2021006833

Fabrizio, V. A., Boelens, J. J., Mauguen, A., Baggott, C., Prabhu, S., Egeler, E., Mavroukakis, S., Pacenta, H., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J.-A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., … Curran, K. J. (2022). Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Advances, 6(7), 1961–1968. https://doi.org/10.1182/bloodadvances.2021006418

Gregory, G. P., Kumar, S., Wang, D., Mahadevan, D., Walker, P., Wagner-Johnston, N., Escobar, C., Bannerji, R., Bhutani, D., Chang, J., Hernandez-Ilizaliturri, F. J., Klein, A., Pagel, J. M., Rybka, W., Yee, A. J., Mohrbacher, A., Huang, M., Farooqui, M., Marinello, P., & Quach, H. (2022). Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances, 6(4), 1232–1242. https://doi.org/10.1182/bloodadvances.2021005872

Tran, T. H., Langlois, S., Meloche, C., Caron, M., Saint-Onge, P., Rouette, A., Bataille, A. R., Jimenez-Cortes, C., Sontag, T., Bittencourt, H., Laverdière, C., Lavallée, V.-P., Leclerc, J.-M., Cole, P. D., Gennarini, L. M., Kahn, J. M., Kelly, K. M., Michon, B., Santiago, R., … Sinnett, D. (2022). Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001. Blood Advances, 6(4), 1329–1341. https://doi.org/10.1182/bloodadvances.2021005634

Menghrajani, K., Gomez-Arteaga, A., Madero-Marroquin, R., Zhang, M.-J., Bo-Subait, K., Sanchez, J., Wang, H.-L., Aljurf, M., Assal, A., Bacher, V. U., Badawy, S. M., Bejanyan, N., Bhatt, V. R., Bredeson, C., Byrne, M., Castillo, P., Cerny, J., Chhabra, S., Ciurea, S. O., … Saber, W. (2022). Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 6(3), 828–847. https://doi.org/10.1182/bloodadvances.2021004881

Cuker, A., Tseng, E. K., Nieuwlaat, R., Angchaisuksiri, P., Blair, C., Dane, K., Davila, J., DeSancho, M. T., Diuguid, D., Griffin, D. O., Kahn, S. R., Klok, F. A., Lee, A. I., Neumann, I., Pai, A., Righini, M., Sanfilippo, K. M., Siegal, D., Skara, M., … Schünemann, H. J. (2022). American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Advances, 6(2), 664–671. https://doi.org/10.1182/bloodadvances.2021005945

Fabrizio, V. A., Phillips, C. L., Lane, A., Baggott, C., Prabhu, S., Egeler, E., Mavroukakis, S., Pacenta, H., Rossoff, J., Stefanski, H. E., Talano, J.-A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., … Schultz, L. M. (2022). Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Advances, 6(2), 600–610. https://doi.org/10.1182/bloodadvances.2021005564